

PATIENT SAFETY CARD



Important Safety Information for Patients Taking Ultomiris®

Ultomiris can lower the ability of your immune system to fight infections, **especially meningococcal infection, which requires immediate medical attention**. If you experience any of the following symptoms, you should **immediately call your doctor or seek emergency medical care, preferably in a major emergency medical care center**:

- headache with nausea or vomiting
- headache with a stiff neck or stiff back
- fever
- rash
- confusion
- muscle aches with flu-like symptoms
- eyes sensitive to light



Get emergency medical care right away if you have any of these signs or symptoms and show this card.

Keep this card with you at all times during treatment and for 8 months after your last Ultomiris® dose. Your risk of meningococcal infection may continue for several months after your last dose of Ultomiris®.

Side effects can be reported to the Israeli Ministry of Health by clicking on the link "Report Side Effects of Drug Treatment" that appears on the homepage of the Ministry of Health's website (www.health.gov.il) which links to a portal, or by the following link: <https://sideeffects.health.gov.il/> and by emailing the Registration Holder's Patient Safety Unit at drugsafety@neopharmgroup.com
Tel 1-800-250-25

PATIENT SAFETY CARD

+ Information for the Treating Physician



This patient has been prescribed **Ultomiris[®]** (ravulizumab) therapy, which increases the patient's susceptibility to meningococcal infection (*Neisseria meningitidis*) or other general infections.

- Meningococcal infections may become rapidly life-threatening or fatal if not recognised and treated early
- **Evaluate immediately if infection is suspected and treat with appropriate antibiotics if necessary**
- Contact prescribing physician (below) as soon as possible

For more information about Ultomiris[®], please review the Physician Leaflet for Ultomiris[®] approved by the Israeli Ministry of Health.

In case of any safety problems, call tel': **1-800-250-255** or e-mail to: **drugsafety@neopharmgroup.com**

+ **Patients receiving Ultomiris should carry this card at all times. Show this card to any doctor involved in your health care.**

Patient Name _____

Hospital where treated _____

Physician name _____

Tel. number _____



This patient safety card was last approved in February 2020 by The Israeli Ministry of Health (MOH)



Alexion Pharma Israel Ltd.
Beit Neopharm, 6 Hashiloach St., P.O.B. 7063,
Petach Tikva, 4917001, Tel: 1-800-250-255